NCT04390139View on ClinicalTrials.gov

Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 13, 2020

Primary Completion Date

December 20, 2022

Study Completion Date

December 20, 2022

Conditions

COVID-19SARS-CoV 2Adult Respiratory Distress Syndrome

Interventions

DRUG

XCEL-UMC-BETA

Administration on top of the standard administered treatment

OTHER

Placebo

Administration on top of the standard administered treatment

Trial Locations (5)

08907

Hospital de Bellvitge, L'Hospitalet de Llobregat

08221

Mútua de Terrassa, Terrassa

08003

Hospital del Mar, Barcelona

08035

Hospital Vall d'Hebron, Barcelona

08036

Hospital Clínic de Barcelona, Barcelona

All Listed Sponsors

lead

Banc de Sang i Teixits

OTHER

NCT04390139 - Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19 | Biotech Hunter | Biotech Hunter